Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 275 participants.

Also called NCT06688123

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 275 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06688123
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06688123. Randomized; no masking; primary purpose treatment. Start 2025-01-08 (actual); primary completion 2026-04-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
Intervention (Drug)
SHR-3167
Intervention (Drug)
SHR-3167
Intervention (Drug)
Insulin glargine
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06688123
Content hash
0589acf3cb2744c13b3e8ddda8003528f157db6a7f879f8f2df3295bd03066b1